Saltar al contenido
Merck

Chorioamnionitis, neuroinflammation, and injury: timing is key in the preterm ovine fetus.

Journal of neuroinflammation (2018-04-21)
Ruth Gussenhoven, Rob J J Westerlaken, Daan R M G Ophelders, Alan H Jobe, Matthew W Kemp, Suhas G Kallapur, Luc J Zimmermann, Per T Sangild, Stanislava Pankratova, Pierre Gressens, Boris W Kramer, Bobbi Fleiss, Tim G A M Wolfs
RESUMEN

Antenatal infection (i.e., chorioamnionitis) is an important risk factor for adverse neurodevelopmental outcomes after preterm birth. Destructive and developmental disturbances of the white matter are hallmarks of preterm brain injury. Understanding the temporal effects of antenatal infection in relation to the onset of neurological injury is crucial for the development of neurotherapeutics for preterm infants. However, these dynamics remain unstudied. Time-mated ewes were intra-amniotically injected with lipopolysaccharide at 5, 12, or 24 h or 2, 4, 8, or 15 days before preterm delivery at 125 days gestational age (term ~ 150 days). Post mortem analyses for peripheral immune activation, neuroinflammation, and white matter/neuronal injury were performed. Moreover, considering the neuroprotective potential of erythropoietin (EPO) for perinatal brain injury, we evaluated (phosphorylated) EPO receptor (pEPOR) expression in the fetal brain following LPS exposure. Intra-amniotic exposure to this single bolus of LPS resulted in a biphasic systemic IL-6 and IL-8 response. In the developing brain, intra-amniotic LPS exposure induces a persistent microgliosis (IBA-1 immunoreactivity) but a shorter-lived increase in the pro-inflammatory marker COX-2. Cell death (caspase-3 immunoreactivity) was only observed when LPS exposure was greater than 8 days in the white matter, and there was a reduction in the number of (pre) oligodendrocytes (Olig2- and PDGFRα-positive cells) within the white matter at 15 days post LPS exposure only. pEPOR expression displayed a striking biphasic regulation following LPS exposure which may help explain contradicting results among clinical trials that tested EPO for the prevention of preterm brain injury. We provide increased understanding of the spatiotemporal pathophysiological changes in the preterm brain following intra-amniotic inflammation which may aid development of new interventions or implement interventions more effectively to prevent perinatal brain damage.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-Olig-2, Chemicon®, from rabbit
Sigma-Aldrich
Monoclonal Anti-MAP2 antibody produced in mouse, clone HM-2, purified from hybridoma cell culture
Sigma-Aldrich
Anticuerpo antiproteína básica de mielina, a.a. 82-87, culture supernatant, clone 12, Chemicon®
Sigma-Aldrich
Monoclonal Anti-CNPase antibody produced in mouse, clone 11-5B, ascites fluid
Sigma-Aldrich
Anti-Interleukin-8 Antibody, clone 8M6, clone 8M6, Chemicon®, from mouse
Sigma-Aldrich
Anti-Interleukin-6 Antibody, clone 4B6, clone 4B6, Chemicon®, from mouse
Sigma-Aldrich
Anti-Interleukin-6 Antibody, serum, Chemicon®